{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T11:31:37Z","timestamp":1793705497452,"version":"4.5.1"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T00:00:00Z","timestamp":1729123200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T00:00:00Z","timestamp":1729123200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Hum Genet"],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Constitutional mismatch repair deficiency (CMMRD), first described 25 years ago, confers an extremely high and lifelong cancer risk, including haematologic, brain, and gastrointestinal tract malignancies, and is associated with several non-neoplastic features. Our understanding of this condition has improved and novel assays to assist CMMRD diagnosis have been developed. Surveillance protocols need adjustment taking into account recent observational prospective studies assessing their effectiveness. Response to immune checkpoint inhibitors and the effectiveness and toxicity of other treatments have been described. An update and merging of the different guidelines on diagnosis and clinical management of CMMRD into one comprehensive guideline was needed. Seventy-two expert members of the European Reference Network GENTURIS and\/or the European care for CMMRD consortium and one patient representative developed recommendations for CMMRD diagnosis, genetic counselling, surveillance, quality of life, and clinical management based on a systematic literature search and comprehensive literature review and a modified Delphi process. Recommendations for the diagnosis of CMMRD provide testing criteria, propose strategies for CMMRD testing, and define CMMRD diagnostic criteria. Recommendations for surveillance cover each CMMRD-associated tumour type and contain information on starting age, frequency, and surveillance modality. Recommendations for clinical management cover cancer treatment, management of benign tumours or non-neoplastic features, and chemoprevention. Recommendations also address genetic counselling and quality of life. Based on existing guidelines and currently available data, we present 82 recommendations to improve and standardise the care of CMMRD patients in Europe. These recommendations are not meant to be prescriptive and may be adjusted based on individual decisions.<\/jats:p>","DOI":"10.1038\/s41431-024-01708-6","type":"journal-article","created":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T09:02:52Z","timestamp":1729155772000},"page":"1526-1541","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["ERN GENTURIS guidelines on constitutional mismatch repair deficiency diagnosis, genetic counselling, surveillance, quality of life, and clinical management"],"prefix":"10.1038","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9146-9346","authenticated-orcid":false,"given":"Chrystelle","family":"Colas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00e9a","family":"Guerrini-Rousseau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7058-6973","authenticated-orcid":false,"given":"Manon","family":"Suerink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Gallon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4120-5873","authenticated-orcid":false,"given":"Christian P.","family":"Kratz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c9lo\u00efse","family":"Ayuso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"ERN GENTURIS CMMRD Guideline Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe","family":"Andreiuolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1347-6644","authenticated-orcid":false,"given":"Amedeo A.","family":"Azizi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Beccaria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgit","family":"Burkhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice","family":"Claret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Volodia","family":"Dangouloff-ros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youenn","family":"Drouet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjolijn C. J.","family":"Jongmans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mari\u00ebtte","family":"van Kouwen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Ruiz-Ponte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magali","family":"Svrcek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Member of the European Reference Network on Genetic Tumour Risk Syndromes (ERN GENTURIS)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Member of the European consortium Care for CMMRD (C4CMMRD)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Brugi\u00e8res","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0732-7538","authenticated-orcid":false,"given":"Katharina","family":"Wimmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,17]]},"reference":[{"key":"1708_CR1","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1038\/s43018-021-00200-0","volume":"2","author":"X Zou","year":"2021","unstructured":"Zou X, Koh GCC, Nanda AS, Degasperi A, Urgo K, Roumeliotis TI, et al. A systematic CRISPR screen defines mutational mechanisms underpinning signatures caused by replication errors and endogenous DNA damage. Nat Cancer. 2021;2:643\u201357.","journal-title":"Nat Cancer"},{"key":"1708_CR2","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/s41436-019-0596-9","volume":"22","author":"M Dominguez-Valentin","year":"2020","unstructured":"Dominguez-Valentin M, Sampson JR, Seppala TT, Ten Broeke SW, Plazzer JP, Nakken S, et al. Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the Prospective Lynch Syndrome Database. Genet Med. 2020;22:15\u201325.","journal-title":"Genet Med"},{"key":"1708_CR3","first-page":"290","volume":"59","author":"MD Ricciardone","year":"1999","unstructured":"Ricciardone MD, Ozcelik T, Cevher B, Ozdag H, Tuncer M, Gurgey A, et al. Human MLH1 deficiency predisposes to hematological malignancy and neurofibromatosis type 1. Cancer Res. 1999;59:290\u20133.","journal-title":"Cancer Res"},{"key":"1708_CR4","first-page":"294","volume":"59","author":"Q Wang","year":"1999","unstructured":"Wang Q, Lasset C, Desseigne F, Frappaz D, Bergeron C, Navarro C, et al. Neurofibromatosis and early onset of cancers in hMLH1-deficient children. Cancer Res. 1999;59:294\u20137.","journal-title":"Cancer Res"},{"key":"1708_CR5","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1093\/nar\/gkad015","volume":"51","author":"SR Bruekner","year":"2023","unstructured":"Bruekner SR, Pieters W, Fish A, Liaci AM, Scheffers S, Rayner E, et al. Unexpected moves: a conformational change in MutSalpha enables high-affinity DNA mismatch binding. Nucleic Acids Res. 2023;51:1173\u201388.","journal-title":"Nucleic Acids Res"},{"key":"1708_CR6","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1136\/jmedgenet-2014-102934","volume":"52","author":"L Li","year":"2015","unstructured":"Li L, Hamel N, Baker K, McGuffin MJ, Couillard M, Gologan A, et al. A homozygous PMS2 founder mutation with an attenuated constitutional mismatch repair deficiency phenotype. J Med Genet. 2015;52:348\u201352.","journal-title":"J Med Genet"},{"key":"1708_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-024-00603-z","volume":"8","author":"R Gallon","year":"2024","unstructured":"Gallon R, Brekelmans C, Martin M, Bours V, Schamschula E, Amberger A, et al. Constitutional mismatch repair deficiency mimicking Lynch syndrome is associated with hypomorphic mismatch repair gene variants. NPJ Precis Oncol. 2024;8:119.","journal-title":"NPJ Precis Oncol"},{"key":"1708_CR8","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1136\/jmedgenet-2013-102238","volume":"51","author":"HF Vasen","year":"2014","unstructured":"Vasen HF, Ghorbanoghli Z, Bourdeaut F, Cabaret O, Caron O, Duval A, et al. Guidelines for surveillance of individuals with constitutional mismatch repair-deficiency proposed by the European Consortium \u201cCare for CMMR-D\u201d (C4CMMR-D). J Med Genet. 2014;51:283\u201393.","journal-title":"J Med Genet"},{"key":"1708_CR9","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1016\/S1470-2045(24)00026-3","volume":"25","author":"AB Ercan","year":"2024","unstructured":"Ercan AB, Aronson M, Fernandez NR, Chang Y, Levine A, Liu ZA, et al. Clinical and biological landscape of constitutional mismatch-repair deficiency syndrome: an International Replication Repair Deficiency Consortium cohort study. Lancet Oncol. 2024;25:668\u201382.","journal-title":"Lancet Oncol"},{"key":"1708_CR10","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1111\/cge.12904","volume":"91","author":"K Wimmer","year":"2017","unstructured":"Wimmer K, Rosenbaum T, Messiaen L. Connections between constitutional mismatch repair deficiency syndrome and neurofibromatosis type 1. Clin Genet. 2017;91:507\u201319.","journal-title":"Clin Genet"},{"key":"1708_CR11","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1053\/j.gastro.2017.02.011","volume":"152","author":"C Durno","year":"2017","unstructured":"Durno C, Boland CR, Cohen S, Dominitz JA, Giardiello FM, Johnson DA, et al. Recommendations on Surveillance and Management of Biallelic Mismatch Repair Deficiency (BMMRD) Syndrome: A Consensus Statement by the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology. 2017;152:1605\u201314.","journal-title":"Gastroenterology"},{"key":"1708_CR12","doi-asserted-by":"publisher","first-page":"2779","DOI":"10.1200\/JCO.20.02636","volume":"39","author":"C Durno","year":"2021","unstructured":"Durno C, Ercan AB, Bianchi V, Edwards M, Aronson M, Galati M, et al. Survival Benefit for Individuals With Constitutional Mismatch Repair Deficiency Undergoing Surveillance. J Clin Oncol. 2021;39:2779\u201390.","journal-title":"J Clin Oncol"},{"key":"1708_CR13","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1136\/jmedgenet-2015-103299","volume":"52","author":"N Lavoine","year":"2015","unstructured":"Lavoine N, Colas C, Muleris M, Bodo S, Duval A, Entz-Werle N, et al. Constitutional mismatch repair deficiency syndrome: clinical description in a French cohort. J Med Genet. 2015;52:770\u20138.","journal-title":"J Med Genet"},{"key":"1708_CR14","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.ejmg.2015.12.014","volume":"59","author":"T Ripperger","year":"2016","unstructured":"Ripperger T, Schlegelberger B. Acute lymphoblastic leukemia and lymphoma in the context of constitutional mismatch repair deficiency syndrome. Eur J Med Genet. 2016;59:133\u201342.","journal-title":"Eur J Med Genet"},{"key":"1708_CR15","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1136\/jmedgenet-2014-102284","volume":"51","author":"K Wimmer","year":"2014","unstructured":"Wimmer K, Kratz CP, Vasen HF, Caron O, Colas C, Entz-Werle N, et al. Diagnostic criteria for constitutional mismatch repair deficiency syndrome: suggestions of the European consortium \u2018care for CMMRD\u2019 (C4CMMRD). J Med Genet. 2014;51:355\u201365.","journal-title":"J Med Genet"},{"key":"1708_CR16","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.3174\/ajnr.A5766","volume":"39","author":"SI Shiran","year":"2018","unstructured":"Shiran SI, Ben-Sira L, Elhasid R, Roth J, Tabori U, Yalon M, et al. Multiple Brain Developmental Venous Anomalies as a Marker for Constitutional Mismatch Repair Deficiency Syndrome. AJNR Am J Neuroradiol. 2018;39:1943\u20136.","journal-title":"AJNR Am J Neuroradiol"},{"key":"1708_CR17","doi-asserted-by":"publisher","unstructured":"Raveneau M, Guerrini-Rousseau L, Levy R, Roux C, Bolle S, Doz F, et al. Specific brain MRI features of constitutional mismatch repair deficiency syndrome in children with high-grade gliomas. Eur Radiol. 2024. https:\/\/doi.org\/10.1007\/s00330-024-10885-3. Online ahead of print.","DOI":"10.1007\/s00330-024-10885-3"},{"key":"1708_CR18","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.3389\/fimmu.2018.01506","volume":"9","author":"VK Tesch","year":"2018","unstructured":"Tesch VK, H IJ, Raicht A, Rueda D, Dominguez-Pinilla N, Allende LM, et al. No Overt Clinical Immunodeficiency Despite Immune Biological Abnormalities in Patients With Constitutional Mismatch Repair Deficiency. Front Immunol. 2018;9:1506.","journal-title":"Front Immunol"},{"key":"1708_CR19","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1038\/s41436-020-0925-z","volume":"22","author":"JA Perez-Valencia","year":"2020","unstructured":"Perez-Valencia JA, Gallon R, Chen Y, Koch J, Keller M, Oberhuber K, et al. Constitutional mismatch repair deficiency is the diagnosis in 0.41% of pathogenic NF1\/SPRED1 variant negative children suspected of sporadic neurofibromatosis type 1. Genet Med. 2020;22:2081\u20138.","journal-title":"Genet Med"},{"key":"1708_CR20","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1136\/jmedgenet-2018-105664","volume":"56","author":"M Suerink","year":"2019","unstructured":"Suerink M, Ripperger T, Messiaen L, Menko FH, Bourdeaut F, Colas C, et al. Constitutional mismatch repair deficiency as a differential diagnosis of neurofibromatosis type 1: consensus guidelines for testing a child without malignancy. J Med Genet. 2019;56:53\u201362.","journal-title":"J Med Genet"},{"key":"1708_CR21","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1158\/1055-9965.EPI-16-0693","volume":"26","author":"AK Win","year":"2017","unstructured":"Win AK, Jenkins MA, Dowty JG, Antoniou AC, Lee A, Giles GG, et al. Prevalence and Penetrance of Major Genes and Polygenes for Colorectal Cancer. Cancer Epidemiol Biomark Prev. 2017;26:404\u201312.","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"1708_CR22","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1053\/j.gastro.2015.06.013","volume":"149","author":"S Bodo","year":"2015","unstructured":"Bodo S, Colas C, Buhard O, Collura A, Tinat J, Lavoine N, et al. Diagnosis of Constitutional Mismatch Repair-Deficiency Syndrome Based on Microsatellite Instability and Lymphocyte Tolerance to Methylating Agents. Gastroenterology. 2015;149:1017\u201329.e3.","journal-title":"Gastroenterology"},{"key":"1708_CR23","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1158\/2159-8290.CD-20-0790","volume":"11","author":"J Chung","year":"2021","unstructured":"Chung J, Maruvka YE, Sudhaman S, Kelly J, Haradhvala NJ, Bianchi V, et al. DNA Polymerase and Mismatch Repair Exert Distinct Microsatellite Instability Signatures in Normal and Malignant Human Cells. Cancer Discov. 2021;11:1176\u201391.","journal-title":"Cancer Discov"},{"key":"1708_CR24","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1200\/JCO.21.02873","volume":"41","author":"J Chung","year":"2023","unstructured":"Chung J, Negm L, Bianchi V, Stengs L, Das A, Liu ZA, et al. Genomic Microsatellite Signatures Identify Germline Mismatch Repair Deficiency and Risk of Cancer Onset. J Clin Oncol. 2023;41:766\u201377.","journal-title":"J Clin Oncol"},{"key":"1708_CR25","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1002\/humu.23721","volume":"40","author":"R Gallon","year":"2019","unstructured":"Gallon R, Muhlegger B, Wenzel SS, Sheth H, Hayes C, Aretz S, et al. A sensitive and scalable microsatellite instability assay to diagnose constitutional mismatch repair deficiency by sequencing of peripheral blood leukocytes. Hum Mutat. 2019;40:649\u201355.","journal-title":"Hum Mutat"},{"key":"1708_CR26","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1053\/j.gastro.2022.12.017","volume":"164","author":"R Gallon","year":"2023","unstructured":"Gallon R, Phelps R, Hayes C, Brugieres L, Guerrini-Rousseau L, Colas C, et al. Constitutional Microsatellite Instability, Genotype, and Phenotype Correlations in Constitutional Mismatch Repair Deficiency. Gastroenterology. 2023;164:579\u201392e8.","journal-title":"Gastroenterology"},{"key":"1708_CR27","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1136\/jmedgenet-2019-106272","volume":"57","author":"M Gonzalez-Acosta","year":"2020","unstructured":"Gonzalez-Acosta M, Marin F, Puliafito B, Bonifaci N, Fernandez A, Navarro M, et al. High-sensitivity microsatellite instability assessment for the detection of mismatch repair defects in normal tissue of biallelic germline mismatch repair mutation carriers. J Med Genet. 2020;57:269\u201373.","journal-title":"J Med Genet"},{"key":"1708_CR28","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1002\/humu.22311","volume":"34","author":"D Ingham","year":"2013","unstructured":"Ingham D, Diggle CP, Berry I, Bristow CA, Hayward BE, Rahman N, et al. Simple detection of germline microsatellite instability for diagnosis of constitutional mismatch repair cancer syndrome. Hum Mutat. 2013;34:847\u201352.","journal-title":"Hum Mutat"},{"key":"1708_CR29","doi-asserted-by":"publisher","first-page":"e32","DOI":"10.1158\/1078-0432.CCR-17-0574","volume":"23","author":"U Tabori","year":"2017","unstructured":"Tabori U, Hansford JR, Achatz MI, Kratz CP, Plon SE, Frebourg T, et al. Clinical Management and Tumor Surveillance Recommendations of Inherited Mismatch Repair Deficiency in Childhood. Clin Cancer Res. 2017;23:e32\u2013e7.","journal-title":"Clin Cancer Res"},{"key":"1708_CR30","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1136\/jmg-2022-108829","volume":"60","author":"Z Ghorbanoghli","year":"2023","unstructured":"Ghorbanoghli Z, van Kouwen M, Versluys B, Bonnet D, Devalck C, Tinat J, et al. High yield of surveillance in patients diagnosed with constitutional mismatch repair deficiency. J Med Genet. 2023;60:679\u201384.","journal-title":"J Med Genet"},{"key":"1708_CR31","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/ng.3202","volume":"47","author":"A Shlien","year":"2015","unstructured":"Shlien A, Campbell BB, de Borja R, Alexandrov LB, Merico D, Wedge D, et al. Combined hereditary and somatic mutations of replication error repair genes result in rapid onset of ultra-hypermutated cancers. Nat Genet. 2015;47:257\u201362.","journal-title":"Nat Genet"},{"key":"1708_CR32","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1002\/path.4957","volume":"243","author":"MA Andrianova","year":"2017","unstructured":"Andrianova MA, Chetan GK, Sibin MK, McKee T, Merkler D, Narasinga RK, et al. Germline PMS2 and somatic POLE exonuclease mutations cause hypermutability of the leading DNA strand in biallelic mismatch repair deficiency syndrome brain tumours. J Pathol. 2017;243:331\u201341.","journal-title":"J Pathol"},{"key":"1708_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-04002-4","volume":"9","author":"NJ Haradhvala","year":"2018","unstructured":"Haradhvala NJ, Kim J, Maruvka YE, Polak P, Rosebrock D, Livitz D, et al. Distinct mutational signatures characterize concurrent loss of polymerase proofreading and mismatch repair. Nat Commun. 2018;9:1746.","journal-title":"Nat Commun"},{"key":"1708_CR34","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1158\/2159-8290.CD-20-0522","volume":"10","author":"D Sha","year":"2020","unstructured":"Sha D, Jin Z, Budczies J, Kluck K, Stenzinger A, Sinicrope FA. Tumor Mutational Burden as a Predictive Biomarker in Solid Tumors. Cancer Discov. 2020;10:1808\u201325.","journal-title":"Cancer Discov"},{"key":"1708_CR35","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1038\/s41591-021-01581-6","volume":"28","author":"A Das","year":"2022","unstructured":"Das A, Sudhaman S, Morgenstern D, Coblentz A, Chung J, Stone SC, et al. Genomic predictors of response to PD-1 inhibition in children with germline DNA replication repair deficiency. Nat Med. 2022;28:125\u201335.","journal-title":"Nat Med"},{"key":"1708_CR36","doi-asserted-by":"publisher","first-page":"e2100286","DOI":"10.1200\/PO.21.00286","volume":"6","author":"JJ Henderson","year":"2022","unstructured":"Henderson JJ, Das A, Morgenstern DA, Sudhaman S, Bianchi V, Chung J, et al. Immune Checkpoint Inhibition as Single Therapy for Synchronous Cancers Exhibiting Hypermutation: An IRRDC Study. JCO Precis Oncol. 2022;6:e2100286.","journal-title":"JCO Precis Oncol"},{"key":"1708_CR37","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1158\/2159-8290.CD-23-0559","volume":"14","author":"A Das","year":"2024","unstructured":"Das A, Fernandez NR, Levine A, Bianchi V, Stengs LK, Chung J, et al. Combined Immunotherapy Improves Outcome for Replication-Repair-Deficient (RRD) High-Grade Glioma Failing Anti-PD-1 Monotherapy: A Report from the International RRD Consortium. Cancer Discov. 2024;14:258\u201373.","journal-title":"Cancer Discov"},{"key":"1708_CR38","doi-asserted-by":"publisher","first-page":"4234","DOI":"10.1158\/0008-5472.CAN-22-2036","volume":"82","author":"T Gan","year":"2022","unstructured":"Gan T, Wang Y, Xie M, Wang Q, Zhao S, Wang P, et al. MEX3A Impairs DNA Mismatch Repair Signaling and Mediates Acquired Temozolomide Resistance in Glioblastoma. Cancer Res. 2022;82:4234\u201346.","journal-title":"Cancer Res"},{"key":"1708_CR39","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1136\/jmedgenet-2020-107627","volume":"59","author":"M Aronson","year":"2022","unstructured":"Aronson M, Colas C, Shuen A, Hampel H, Foulkes WD, Baris Feldman H, et al. Diagnostic criteria for constitutional mismatch repair deficiency (CMMRD): recommendations from the international consensus working group. J Med Genet. 2022;59:318\u201327.","journal-title":"J Med Genet"},{"key":"1708_CR40","doi-asserted-by":"publisher","DOI":"10.1093\/noajnl\/vdz033","volume":"1","author":"L Guerrini-Rousseau","year":"2019","unstructured":"Guerrini-Rousseau L, Varlet P, Colas C, Andreiuolo F, Bourdeaut F, Dahan K, et al. Constitutional mismatch repair deficiency-associated brain tumors: report from the European C4CMMRD consortium. Neuro Oncol Adv. 2019;1:vdz033.","journal-title":"Neuro Oncol Adv"},{"key":"1708_CR41","doi-asserted-by":"publisher","first-page":"904","DOI":"10.3174\/ajnr.A6512","volume":"41","author":"A Kerpel","year":"2020","unstructured":"Kerpel A, Yalon M, Soudack M, Chiang J, Gajjar A, Nichols KE, et al. Neuroimaging Findings in Children with Constitutional Mismatch Repair Deficiency Syndrome. AJNR Am J Neuroradiol. 2020;41:904\u201310.","journal-title":"AJNR Am J Neuroradiol"},{"key":"1708_CR42","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1111\/pde.14861","volume":"39","author":"JM Vassantachart","year":"2022","unstructured":"Vassantachart JM, Zacher NC, Teng JMC. Eruptive nevi in a patient with constitutional mismatch repair deficiency (CMMRD). Pediatr Dermatol. 2022;39:91\u20133.","journal-title":"Pediatr Dermatol"},{"key":"1708_CR43","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1136\/jmedgenet-2019-106303","volume":"57","author":"H Toledano","year":"2020","unstructured":"Toledano H, Orenstein N, Sofrin E, Ruhrman-Shahar N, Amarilyo G, Basel-Salmon L, et al. Paediatric systemic lupus erythematosus as a manifestation of constitutional mismatch repair deficiency. J Med Genet. 2020;57:505\u20138.","journal-title":"J Med Genet"},{"key":"1708_CR44","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.mrfmmm.2007.08.003","volume":"637","author":"H Alotaibi","year":"2008","unstructured":"Alotaibi H, Ricciardone MD, Ozturk M. Homozygosity at variant MLH1 can lead to secondary mutation in NF1, neurofibromatosis type I and early onset leukemia. Mutat Res. 2008;637:209\u201314.","journal-title":"Mutat Res"},{"key":"1708_CR45","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1136\/jmg-2023-109235","volume":"61","author":"L Guerrini-Rousseau","year":"2024","unstructured":"Guerrini-Rousseau L, Pasmant E, Muleris M, Abbou S, Adam-De-Beaumais T, Brugieres L, et al. Neurofibromatosis type 1 mosaicism in patients with constitutional mismatch repair deficiency. J Med Genet. 2024;61:158\u201362.","journal-title":"J Med Genet"},{"key":"1708_CR46","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1093\/jnci\/djac151","volume":"114","author":"CP Kratz","year":"2022","unstructured":"Kratz CP, Smirnov D, Autry R, Jager N, Waszak SM, Grosshennig A, et al. Heterozygous BRCA1 and BRCA2 and Mismatch Repair Gene Pathogenic Variants in Children and Adolescents With Cancer. J Natl Cancer Inst. 2022;114:1523\u201332.","journal-title":"J Natl Cancer Inst"},{"key":"1708_CR47","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1038\/gim.2016.58","volume":"18","author":"D Mandelker","year":"2016","unstructured":"Mandelker D, Schmidt RJ, Ankala A, McDonald Gibson K, Bowser M, Sharma H, et al. Navigating highly homologous genes in a molecular diagnostic setting: a resource for clinical next-generation sequencing. Genet Med. 2016;18:1282\u20139.","journal-title":"Genet Med"},{"key":"1708_CR48","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1002\/humu.24299","volume":"43","author":"A Sehested","year":"2022","unstructured":"Sehested A, Meade J, Scheie D, Ostrup O, Bertelsen B, Misiakou MA, et al. Constitutional POLE variants causing a phenotype reminiscent of constitutional mismatch repair deficiency. Hum Mutat. 2022;43:85\u201396.","journal-title":"Hum Mutat"},{"key":"1708_CR49","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.3390\/biom12101350","volume":"12","author":"E Schamschula","year":"2022","unstructured":"Schamschula E, Kinzel M, Wernstedt A, Oberhuber K, Gottschling H, Schnaiter S, et al. Teenage-Onset Colorectal Cancers in a Digenic Cancer Predisposition Syndrome Provide Clues for the Interaction between Mismatch Repair and Polymerase delta Proofreading Deficiency in Tumorigenesis. Biomolecules. 2022;12:1350.","journal-title":"Biomolecules"},{"key":"1708_CR50","doi-asserted-by":"publisher","first-page":"e14","DOI":"10.1158\/1078-0432.CCR-17-0428","volume":"23","author":"CC Porter","year":"2017","unstructured":"Porter CC, Druley TE, Erez A, Kuiper RP, Onel K, Schiffman JD, et al. Recommendations for Surveillance for Children with Leukemia-Predisposing Conditions. Clin Cancer Res. 2017;23:e14\u201322.","journal-title":"Clin Cancer Res"},{"key":"1708_CR51","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.canlet.2017.06.018","volume":"403","author":"H Westdorp","year":"2017","unstructured":"Westdorp H, Kolders S, Hoogerbrugge N, de Vries IJM, Jongmans MCJ, Schreibelt G. Immunotherapy holds the key to cancer treatment and prevention in constitutional mismatch repair deficiency (CMMRD) syndrome. Cancer Lett. 2017;403:159\u201364.","journal-title":"Cancer Lett"},{"key":"1708_CR52","doi-asserted-by":"publisher","first-page":"E1037","DOI":"10.1055\/a-0591-9054","volume":"6","author":"Y Shimamura","year":"2018","unstructured":"Shimamura Y, Walsh CM, Cohen S, Aronson M, Tabori U, Kortan PP, et al. Role of video capsule endoscopy in patients with constitutional mismatch repair deficiency (CMMRD) syndrome: report from the International CMMRD Consortium. Endosc Int Open. 2018;6:E1037\u201343.","journal-title":"Endosc Int Open"},{"key":"1708_CR53","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1001\/jamaoncol.2017.1355","volume":"3","author":"ML Ballinger","year":"2017","unstructured":"Ballinger ML, Ferris NJ, Moodie K, Mitchell G, Shanley S, James PA, et al. Surveillance in Germline TP53 Mutation Carriers Utilizing Whole-Body Magnetic Resonance Imaging. JAMA Oncol. 2017;3:1735\u20136.","journal-title":"JAMA Oncol"},{"key":"1708_CR54","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1038\/s41431-020-0638-4","volume":"28","author":"T Frebourg","year":"2020","unstructured":"Frebourg T, Bajalica Lagercrantz S, Oliveira C, Magenheim R, Evans DG. European Reference Network G. Guidelines for the Li-Fraumeni and heritable TP53-related cancer syndromes. Eur J Hum Genet. 2020;28:1379\u201386.","journal-title":"Eur J Hum Genet"},{"key":"1708_CR55","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1007\/s00247-022-05296-9","volume":"52","author":"N Tewattanarat","year":"2022","unstructured":"Tewattanarat N, Junhasavasdikul T, Panwar S, Joshi SD, Abadeh A, Greer MLC, et al. Diagnostic accuracy of imaging approaches for early tumor detection in children with Li-Fraumeni syndrome. Pediatr Radio. 2022;52:1283\u201395.","journal-title":"Pediatr Radio"},{"key":"1708_CR56","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/s41586-020-2209-9","volume":"580","author":"M Touat","year":"2020","unstructured":"Touat M, Li YY, Boynton AN, Spurr LF, Iorgulescu JB, Bohrson CL, et al. Mechanisms and therapeutic implications of hypermutation in gliomas. Nature. 2020;580:517\u201323.","journal-title":"Nature"},{"key":"1708_CR57","doi-asserted-by":"publisher","unstructured":"Rigaud C, Forster VJ, Al-Tarrah H, Attarbaschi A, Bianchi V, Burke A, et al. Comprehensive analysis of constitutional mismatch repair deficiency-associated non-Hodgkin lymphomas in a global cohort. Pediatr Blood Cancer. 2024:e31302. https:\/\/doi.org\/10.1002\/pbc.31302. Online ahead of print.","DOI":"10.1002\/pbc.31302"},{"key":"1708_CR58","doi-asserted-by":"publisher","first-page":"2735","DOI":"10.1200\/JCO.21.02691","volume":"40","author":"Z Jin","year":"2022","unstructured":"Jin Z, Sinicrope FA. Mismatch Repair-Deficient Colorectal Cancer: Building on Checkpoint Blockade. J Clin Oncol. 2022;40:2735\u201350.","journal-title":"J Clin Oncol"},{"key":"1708_CR59","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1097\/MPG.0000000000002247","volume":"68","author":"W Hyer","year":"2019","unstructured":"Hyer W, Cohen S, Attard T, Vila-Miravet V, Pienar C, Auth M, et al. Management of Familial Adenomatous Polyposis in Children and Adolescents: Position Paper From the ESPGHAN Polyposis Working Group. J Pediatr Gastroenterol Nutr. 2019;68:428\u201341.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"1708_CR60","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1055\/a-1016-4977","volume":"51","author":"ME van Leerdam","year":"2019","unstructured":"van Leerdam ME, Roos VH, van Hooft JE, Balaguer F, Dekker E, Kaminski MF, et al. Endoscopic management of Lynch syndrome and of familial risk of colorectal cancer: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy. 2019;51:1082\u201393.","journal-title":"Endoscopy"},{"key":"1708_CR61","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/nature25480","volume":"555","author":"SN Gr\u00f6bner","year":"2018","unstructured":"Gr\u00f6bner SN, Worst BC, Weischenfeldt J, Buchhalter I, Kleinheinz K, Rudneva VA, et al. The landscape of genomic alterations across childhood cancers. Nature. 2018;555:321\u20137.","journal-title":"Nature"},{"key":"1708_CR62","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1038\/s41375-020-0841-x","volume":"35","author":"A Attarbaschi","year":"2021","unstructured":"Attarbaschi A, Carraro E, Ronceray L, Andres M, Barzilai-Birenboim S, Bomken S, et al. Second malignant neoplasms after treatment of non-Hodgkin\u2019s lymphoma-a retrospective multinational study of 189 children and adolescents. Leukemia. 2021;35:534\u201349.","journal-title":"Leukemia"},{"key":"1708_CR63","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1016\/j.cgh.2020.06.034","volume":"19","author":"RM de Voer","year":"2021","unstructured":"de Voer RM, Diets IJ, van der Post RS, Weren RDA, Kamping EJ, de Bitter TJJ, et al. Clinical, Pathology, Genetic, and Molecular Features of Colorectal Tumors in Adolescents and Adults 25 Years or Younger. Clin Gastroenterol Hepatol. 2021;19:1642\u201351.e8.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1708_CR64","doi-asserted-by":"publisher","first-page":"e668","DOI":"10.1097\/HS9.0000000000000668","volume":"6","author":"E Kroeze","year":"2022","unstructured":"Kroeze E, Weijers DD, Hagleitner MM, de Groot-Kruseman HA, Jongmans MCJ, Kuiper RP, et al. High Prevalence of Constitutional Mismatch Repair Deficiency in a Pediatric T-cell Lymphoblastic Lymphoma Cohort. Hemasphere. 2022;6:e668.","journal-title":"Hemasphere"},{"key":"1708_CR65","doi-asserted-by":"publisher","first-page":"4629","DOI":"10.3390\/ijms22094629","volume":"22","author":"C Carrato","year":"2021","unstructured":"Carrato C, Sanz C, Munoz-Marmol AM, Blanco I, Pineda M, Del Valle J, et al. The Challenge of Diagnosing Constitutional Mismatch Repair Deficiency Syndrome in Brain Malignancies from Young Individuals. Int J Mol Sci. 2021;22:4629.","journal-title":"Int J Mol Sci"},{"key":"1708_CR66","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/s43018-022-00509-4","volume":"4","author":"V Thatikonda","year":"2023","unstructured":"Thatikonda V, Islam SMA, Autry RJ, Jones BC, Grobner SN, Warsow G, et al. Comprehensive analysis of mutational signatures reveals distinct patterns and molecular processes across 27 pediatric cancers. Nat Cancer. 2023;4:276\u201389.","journal-title":"Nat Cancer"},{"key":"1708_CR67","doi-asserted-by":"publisher","first-page":"4503","DOI":"10.1158\/1078-0432.CCR-19-3517","volume":"26","author":"M Kloor","year":"2020","unstructured":"Kloor M, Reuschenbach M, Pauligk C, Karbach J, Rafiyan MR, Al-Batran SE, et al. A Frameshift Peptide Neoantigen-Based Vaccine for Mismatch Repair-Deficient Cancers: A Phase I\/IIa Clinical Trial. Clin Cancer Res. 2020;26:4503\u201310.","journal-title":"Clin Cancer Res"},{"key":"1708_CR68","doi-asserted-by":"publisher","first-page":"3972","DOI":"10.1158\/0008-5472.CAN-20-1072","volume":"80","author":"G Leoni","year":"2020","unstructured":"Leoni G, D\u2019Alise AM, Cotugno G, Langone F, Garzia I, De Lucia M, et al. A Genetic Vaccine Encoding Shared Cancer Neoantigens to Treat Tumors with Microsatellite Instability. Cancer Res. 2020;80:3972\u201382.","journal-title":"Cancer Res"},{"key":"1708_CR69","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1016\/S0140-6736(20)30366-4","volume":"395","author":"J Burn","year":"2020","unstructured":"Burn J, Sheth H, Elliott F, Reed L, Macrae F, Mecklin JP, et al. Cancer prevention with aspirin in hereditary colorectal cancer (Lynch syndrome), 10-year follow-up and registry-based 20-year data in the CAPP2 study: a double-blind, randomised, placebo-controlled trial. Lancet. 2020;395:1855\u201363.","journal-title":"Lancet"},{"key":"1708_CR70","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1038\/s41431-018-0197-0","volume":"26","author":"E Leenders","year":"2018","unstructured":"Leenders E, Westdorp H, Bruggemann RJ, Loeffen J, Kratz C, Burn J, et al. Cancer prevention by aspirin in children with Constitutional Mismatch Repair Deficiency (CMMRD). Eur J Hum Genet. 2018;26:1417\u201323.","journal-title":"Eur J Hum Genet"},{"key":"1708_CR71","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1093\/annonc\/mdz134","volume":"30","author":"AB Schrock","year":"2019","unstructured":"Schrock AB, Ouyang C, Sandhu J, Sokol E, Jin D, Ross JS, et al. Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer. Ann Oncol. 2019;30:1096\u2013103.","journal-title":"Ann Oncol"},{"key":"1708_CR72","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2023.2243169","volume":"12","author":"A Hijazi","year":"2023","unstructured":"Hijazi A, Antoniotti C, Cremolini C, Galon J. Light on life: immunoscore immune-checkpoint, a predictor of immunotherapy response. Oncoimmunology. 2023;12:2243169.","journal-title":"Oncoimmunology"}],"container-title":["European Journal of Human Genetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41431-024-01708-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41431-024-01708-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41431-024-01708-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T10:03:23Z","timestamp":1732874603000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41431-024-01708-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,17]]},"references-count":72,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["1708"],"URL":"https:\/\/doi.org\/10.1038\/s41431-024-01708-6","relation":{},"ISSN":["1018-4813","1476-5438"],"issn-type":[{"value":"1018-4813","type":"print"},{"value":"1476-5438","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,17]]},"assertion":[{"value":"27 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All members of the ERN GENTURIS CMMRD Guideline Group, including the Core Working Group, have provided disclosure statements on all relationships that they have that might be perceived to be a potential conflict of interest. Amedeo Azizi reports receipt of honoraria or consultation fees from Alexion, AstraZeneca and Novartis. Kevin Beccaria reports previous employment with Carthera SAS. Laurence Brugi\u00e8res reports receipts of honoraria or consultation fees from ESAI and TAKEDA. Chrystelle Colas reports receipt of honoraria or consultation fees from AstraZeneca. Volodia Dangouloff-Ros reports receipt of grants\/research support from GE Healthcare. Richard Gallon reports receipt of grants\/research support from Cancer Research UK Catalyst and UK National Health Service. Christian Kratz reports support from BMBF ADDRess (01GM1909A) and Deutsche Kinderkrebsstiftung (DKS2021.25). Magali Svrcek reports receipt of grants\/research support from Bayer and Roche, and receipt of honoraria or consultation fees from Astellas, MSD and Sanofi. All participants of the ERN GENTURIS CMMRD Delphi survey have provided disclosure statements on all relationships that they have that might be perceived to be a potential source of a competing interests. Andishe Attarbaschi reports receipt of honoraria or consultation fees from Amgen, Novartis, Jazz, Gilead and MSD. Patrick Benusiglio reports receipt of honoraria or consultation fees from AstraZeneca, BMS and MSD. Christof Kramm reports receipt of grants\/research support from Deutsche Kinderkrebsstiftung (non-commercial), research collaboration with Bayer to develop NTRK-inhibitors, being a member of the advisory board for Boehringer Ingelheim, and participation in Blueprint Medicines ROVER trial NCT04773782. Eric Legius reports receipt of honoraria or consultation fees from Alexion and AstraZeneca. Rianne Oostenbrink reports receipt of grants\/research support from EU Patient-centric clinical trial platform (EU-PEARL), which includes support from the European Union\u2019s Horizon 2020 research and innovation program, EFPIA, Children\u2019s Tumor Foundation, Global Alliance for TB Drug Development non-profit organization and Springworks Therapeutics Inc., receipt of honoraria or consultation fees from AstraZeneca, and participation in a speaker\u2019s bureau sponsored by Alexion. Enrico Opocher reports receipt of honoraria or consultation fees from Alexion (RareDisease). Markus G. Seidel reports receipt of grants\/research support from Takeda, Amgen and Novartis, and receipt of honoraria or consultation fees from Jazz, Amgen and Novartis.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}